
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
CooperCompanies has demonstrated strong financial performance, with significant growth projected in its MiSight sales, anticipated to increase by 40% year-over-year in FY25, alongside an operating margin that rose to 25.1%, surpassing consensus expectations. The company achieved a gross margin of 68.7%, up 130 basis points from the previous year, indicating effective efficiency gains and a favorable product mix. Furthermore, CooperSurgical's Paragard saw a notable revenue increase of 12% year-over-year, highlighting the company's strong position in both the eyecare and reproductive health markets.
Bears say
The Cooper Companies experienced a weaker than expected organic sales growth in its CooperVision segment, registering +6.4% for the quarter, which fell short of both the forecasted +7.3% and the lower end of the company's FY25 guidance. Additionally, the regions of EMEA and APAC performed below prior year estimates, with APAC's growth hampered by declines in China attributed to specific execution challenges, further contributing to concerns about revenue predictability. The company faces a negative outlook, with bear case scenarios suggesting flat operating margins and low to mid-single digit revenue growth, which could lead to stagnant earnings per share (EPS) projections for FY25 and FY26.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares